Celgene Spreads its Bets in Immuno-Oncology via New Deal with Agios

By Natasha Berry & Heather Cartwright

Pharma Deals Review: Vol 2016 Issue 6 (Table of Contents)

Published: 3 Jun-2016

DOI: 10.3833/pdr.v2016.i6.2162     ISSN: 1756-7874

Section: Research & Development



Celgene has paid existing partner Agios Pharmaceuticals US$200 M upfront in return for opt-in rights to co-develop and co-commercialise therapies based on Agios’ cellular metabolism research platform...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details